Otter Creek Advisors LLC Has $4.99 Million Stock Holdings in Avantor, Inc. (NYSE:AVTR)

Otter Creek Advisors LLC lifted its stake in Avantor, Inc. (NYSE:AVTR – Get Rating) by 23.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 147,519 shares of the company’s stock after acquiring an additional 28,283 shares during the period. Avantor makes up about 2.0% of Otter Creek Advisors LLC’s holdings, making the stock its 7th largest holding. Otter Creek Advisors LLC’s holdings in Avantor were worth $4,987,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. Capital Advisors Ltd. LLC boosted its stake in Avantor by 224.2% during the first quarter. Capital Advisors Ltd. LLC now owns 2,211 shares of the company’s stock valued at $75,000 after buying an additional 1,529 shares during the period. Banco Santander S.A. lifted its stake in Avantor by 1,410.3% during the first quarter. Banco Santander S.A. now owns 153,677 shares of the company’s stock worth $5,197,000 after purchasing an additional 143,502 shares during the last quarter. Brown Advisory Inc. bought a new stake in Avantor during the first quarter worth about $53,261,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in Avantor by 6.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 135,979 shares of the company’s stock worth $4,599,000 after purchasing an additional 8,564 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in Avantor by 224.8% during the first quarter. Qube Research & Technologies Ltd now owns 847,002 shares of the company’s stock worth $28,646,000 after purchasing an additional 586,236 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on AVTR. Robert W. Baird dropped their price target on Avantor from $44.00 to $34.00 and set an “outperform” rating for the company in a research note on Monday, August 1st. Raymond James dropped their price target on Avantor from $40.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, August 1st. Barclays dropped their price target on Avantor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Monday, August 1st. TheStreet upgraded Avantor from a “c” rating to a “b-” rating in a report on Thursday, May 19th. Finally, The Goldman Sachs Group decreased their price objective on Avantor from $42.00 to $37.00 and set a “buy” rating on the stock in a report on Thursday, July 14th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $39.92.

Insiders Place Their Bets

In other news, EVP Frederic Vanderhaegen sold 39,000 shares of the business’s stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $31.61, for a total value of $1,232,790.00. Following the sale, the executive vice president now directly owns 126,764 shares of the company’s stock, valued at approximately $4,007,010.04. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, EVP Gerard Brophy sold 19,603 shares of the business’s stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $31.27, for a total value of $612,985.81. Following the sale, the executive vice president now directly owns 96,935 shares of the company’s stock, valued at approximately $3,031,157.45. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Frederic Vanderhaegen sold 39,000 shares of the company’s stock in a transaction that occurred on Monday, May 23rd. The shares were sold at an average price of $31.61, for a total value of $1,232,790.00. Following the completion of the transaction, the executive vice president now directly owns 126,764 shares in the company, valued at $4,007,010.04. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

Avantor Price Performance

NYSE:AVTR remained flat at $28.55 during mid-day trading on Friday. The company had a trading volume of 4,109,511 shares, compared to its average volume of 6,533,317. Avantor, Inc. has a 52 week low of $27.50 and a 52 week high of $44.37. The firm has a market cap of $19.24 billion, a price-to-earnings ratio of 30.70, a price-to-earnings-growth ratio of 0.71 and a beta of 1.30. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.64 and a quick ratio of 1.18. The firm’s 50-day moving average is $30.72 and its 200 day moving average is $32.46.

Avantor (NYSE:AVTR – Get Rating) last posted its earnings results on Thursday, July 28th. The company reported $0.37 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.01). Avantor had a return on equity of 27.14% and a net margin of 8.27%. The firm had revenue of $1.91 billion for the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter last year, the company posted $0.35 EPS. The firm’s revenue was up 2.7% on a year-over-year basis. As a group, analysts forecast that Avantor, Inc. will post 1.45 EPS for the current year.

About Avantor

(Get Rating)

Avantor, Inc provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.